Al ser el mayor responsable de hospitalizaciones y muertes, la inclusión de varias cepas de A/H3N2 en vacunas de ARN mensajero pueden proporcionar sustanciales beneficios en salud pública
Hsu D, Jayaraman A, Pucci A et al. Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial. Lancet Infect Dis published on line September 5, 2024 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract A la hora de sustituir…
